Studies Chronic inflammatory bowel disease
with ongoing recruitmentCEC-013/CEL
| Target group: | Patients with confirmed coeliac disease who have been on a gluten-free diet for the last 12 months. |
| Study objective: | To evaluate the efficacy of one or more doses of the transglutaminase inhibitor ZED1227 compared to placebo under low gluten exposure. |
Contact person: | Prof. Dr. P. Hasselblatt |
M24-540
| Target group: | Adult patients with moderate to severe ulcerative colitis with intolerance or insufficient effect of conventional therapy (steroids, immunomodulators or mesalazine). |
| Study objective: | Direct comparison of the efficacy of first-line biologics therapy with the IL-23 antibody risankizumab or the integrin antibody vedolizumab. Both preparations are already approved for the treatment of ulcerative colitis, no treatment with placebo. |
Contact person: | Prof. Dr. Peter Hasselblatt |
Fresco
| Target group: | Patients with mild to moderately active ulcerative colitis |
| Study objective: | Efficacy of an oral microbiome transfer ("stool transplant") vs. administration of a microbiome sterile filtrate vs. placebo for the treatment of ulcerative colitis |
Contact person: | Prof. Dr. P. Hasselblatt |
Re-Introduce
| Target group: | Patients with Crohn's disease with a history of TNF antibody treatment failure |
| Study objective: | Efficacy of infliximab re-induction and subcutaneous maintenance therapy |
| Contact person: | Prof. Dr. P. Hasselblatt |
AbbVie M24-885
| Target group: | Patients with moderate to severe Crohn's disease after intolerance or inadequate response to one or more prior therapies in the field of steroids, immunomodulators or biologics |
| Study objective: | Achievement of endoscopic remission at week 12. |
| Contact person: | Prof. Dr. P. Hasselblatt |
Clinnova IBD
| Target group: | Patients with Crohn's disease and ulcerative colitis |
| Aim of the study: | International collaborative project to develop the potential of new biomarkers and artificial intelligence (AI) for customized therapy recommendations |
| Contact person: | Prof. Dr. P. Hasselblatt |
Study Assistance Contact | +49 (0) 761 270-32615 +49 (0) 761 270-32614 |
Project coordination Contact | +49 (0) 761 270-32613 +49 (0) 761 270-32622 |